This study is testing a new medication called icovamenib (100mg) for people with Type 2 Diabetes whose blood sugar levels are not well-controlled, even with current medications. You might be able to join if you are between 18 and 70 years old, have Type 2 Diabetes, and are already taking 1 to 3 common diabetes medications (like metformin, SGLT2 inhibitors, alogliptin, or sitagliptin) at a stable dose. Your HbA1c (a measure of average blood sugar over 2-3 months) should be between 7.5% and 10.5%. The main goal is to see if icovamenib is better than a placebo (an inactive substance) at improving blood sugar control after 12 weeks of treatment, with results measured at 26 weeks.

Study design

This is a Phase 2, randomized, double-blind, placebo-controlled study with a planned enrollment of 60 participants.

What's involved

Participants will receive either icovamenib 100mg or a placebo once daily for 12 weeks, as part of a 52-week study.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome for glycemic control is measured at 26 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.